company background image
2644 logo

LanZhou Foci PharmaceuticalLtd SZSE:002644 Stock Report

Last Price

CN¥7.43

Market Cap

CN¥3.7b

7D

3.3%

1Y

-45.8%

Updated

25 Apr, 2024

Data

Company Financials

LanZhou Foci Pharmaceutical Co.,Ltd.

SZSE:002644 Stock Report

Market Cap: CN¥3.7b

2644 Stock Overview

LanZhou Foci Pharmaceutical Co.,Ltd., a pharmaceutical company, manufactures and sells traditional chinese medicines in China.

2644 fundamental analysis
Snowflake Score
Valuation0/6
Future Growth0/6
Past Performance1/6
Financial Health5/6
Dividends3/6

LanZhou Foci Pharmaceutical Co.,Ltd. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for LanZhou Foci PharmaceuticalLtd
Historical stock prices
Current Share PriceCN¥7.43
52 Week HighCN¥14.94
52 Week LowCN¥5.84
Beta0.20
1 Month Change-5.95%
3 Month Change-10.48%
1 Year Change-45.77%
3 Year Change0.54%
5 Year Change-8.95%
Change since IPO112.51%

Recent News & Updates

LanZhou Foci PharmaceuticalLtd's (SZSE:002644) Weak Earnings May Only Reveal A Part Of The Whole Picture

Apr 17
LanZhou Foci PharmaceuticalLtd's (SZSE:002644) Weak Earnings May Only Reveal A Part Of The Whole Picture

LanZhou Foci Pharmaceutical Co.,Ltd.'s (SZSE:002644) 26% Price Boost Is Out Of Tune With Earnings

Mar 13
LanZhou Foci Pharmaceutical Co.,Ltd.'s (SZSE:002644) 26% Price Boost Is Out Of Tune With Earnings

Recent updates

LanZhou Foci PharmaceuticalLtd's (SZSE:002644) Weak Earnings May Only Reveal A Part Of The Whole Picture

Apr 17
LanZhou Foci PharmaceuticalLtd's (SZSE:002644) Weak Earnings May Only Reveal A Part Of The Whole Picture

LanZhou Foci Pharmaceutical Co.,Ltd.'s (SZSE:002644) 26% Price Boost Is Out Of Tune With Earnings

Mar 13
LanZhou Foci Pharmaceutical Co.,Ltd.'s (SZSE:002644) 26% Price Boost Is Out Of Tune With Earnings

LanZhou Foci Pharmaceutical Co.,Ltd.'s (SZSE:002644) 26% Price Boost Is Out Of Tune With Earnings

Mar 13
LanZhou Foci Pharmaceutical Co.,Ltd.'s (SZSE:002644) 26% Price Boost Is Out Of Tune With Earnings

Shareholder Returns

2644CN PharmaceuticalsCN Market
7D3.3%0.8%-0.4%
1Y-45.8%-13.4%-14.4%

Return vs Industry: 002644 underperformed the CN Pharmaceuticals industry which returned -13.4% over the past year.

Return vs Market: 002644 underperformed the CN Market which returned -14.4% over the past year.

Price Volatility

Is 2644's price volatile compared to industry and market?
2644 volatility
2644 Average Weekly Movement7.8%
Pharmaceuticals Industry Average Movement7.7%
Market Average Movement8.8%
10% most volatile stocks in CN Market12.7%
10% least volatile stocks in CN Market5.2%

Stable Share Price: 002644 has not had significant price volatility in the past 3 months.

Volatility Over Time: 002644's weekly volatility (8%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
19291,353Yingchun Wangwww.fczy.com

LanZhou Foci Pharmaceutical Co.,Ltd., a pharmaceutical company, manufactures and sells traditional chinese medicines in China. The company offers its products in various dosage forms, including pills, tablets, granules, capsules, and gel under the Min Shan and Foci brands. It also engages in research and development of new herbal drugs.

LanZhou Foci Pharmaceutical Co.,Ltd. Fundamentals Summary

How do LanZhou Foci PharmaceuticalLtd's earnings and revenue compare to its market cap?
2644 fundamental statistics
Market capCN¥3.75b
Earnings (TTM)CN¥61.66m
Revenue (TTM)CN¥1.12b

61.5x

P/E Ratio

3.4x

P/S Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report (TTM)
2644 income statement (TTM)
RevenueCN¥1.12b
Cost of RevenueCN¥763.16m
Gross ProfitCN¥355.86m
Other ExpensesCN¥294.20m
EarningsCN¥61.66m

Last Reported Earnings

Mar 31, 2024

Next Earnings Date

n/a

Earnings per share (EPS)0.12
Gross Margin31.80%
Net Profit Margin5.51%
Debt/Equity Ratio2.1%

How did 2644 perform over the long term?

See historical performance and comparison

Dividends

0.4%

Current Dividend Yield

25%

Payout Ratio
Simply Wall Street Pty Ltd (ACN 600 056 611), is a Corporate Authorised Representative (Authorised Representative Number: 467183) of Sanlam Private Wealth Pty Ltd (AFSL No. 337927). Any advice contained in this website is general advice only and has been prepared without considering your objectives, financial situation or needs. You should not rely on any advice and/or information contained in this website and before making any investment decision we recommend that you consider whether it is appropriate for your situation and seek appropriate financial, taxation and legal advice. Please read our Financial Services Guide before deciding whether to obtain financial services from us.